Mechanism and clinical progress of molecular targeted cancer therapy.
- Author:
Hong-xiang HU
;
Xue-qing WANG
;
Hua ZHANG
;
Qiang ZHANG
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors;
Antibodies, Monoclonal;
Drug Delivery Systems;
Humans;
Molecular Targeted Therapy;
Neoplasms;
drug therapy;
Protein Kinase Inhibitors;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors
- From:
Acta Pharmaceutica Sinica
2015;50(10):1232-1239
- CountryChina
- Language:Chinese
-
Abstract:
Molecular target-based cancer therapy is playing a more and more important role in cancer therapy because of its high specificity, good tolerance and so on. There are different kinds of molecular targeted drugs such as monoclonal antibodies and small molecular kinase inhibitors, and more than 50 drugs have been approved since 1997. When the first monoclonal antibody, rituximab, was on the market. The development of molecular target-based cancer therapeutics has become the main approach. Based on this, we summarized the drugs approved by FDA and introduced their mechanism of actions and clinical applications. In order to incorporate most molecular targeted drugs and describe clearly various characteristics, we divided them into four categories: drugs related to EGFR, drugs related to antiangiogenesis, drugs related to specific antigen and other targeted drugs. The purpose of this review is to provide a current status of this field and discover the main problems in the molecular targeted therapy.
